CLSA hires top-ranked pharmaceuticals analyst David Maris
28 August, 2009
Hong Kong - Friday, 28 August 2009 - CLSA Asia-Pacific Markets, Asia's leading independent brokerage and investment group, continues to expand its independent, award-wining research in the US through its U.S. Broker-Dealer affiliate Calyon Securities (USA) Inc. (“CSI”), with the hire of top-ranked pharmaceuticals analyst David Maris.
Maris has been ranked seven times the No. 1 pharmaceuticals industry analyst in the US by Institutional Investor, and ranked No.1 multiple times by Alpha Magazine and in the Greenwich Associates surveys. Maris will cover the specialty pharmaceutical and pharmaceutical groups under the CLSA brand.
Maris joins a growing team of sector specialists that includes noted US banking and financial analyst Mike Mayo, who joined CSI in April to initiate coverage of US financial stocks.
Maris is known for his objective and non-consensus reports, and his pre-emptive call of downturns in stocks. Several of these calls, including Elan and Biovail, received considerable publicity and attention from Wall Street.
On his decision to join CSI and publish under the CLSA brand, Maris said: "CLSA's global reputation for independent insight and a focus on issues that matter fits perfectly with my approach to equity research and is what attracted me to the firm. I can't wait to get started."
CLSA Chairman and Chief Executive Officer Jonathan Slone said the hire of Maris supported CLSA’s strategy to expand the CLSA brand into the US through CSI.
“What we see now across the industry, is a flight by some of the best analysts in the US from the large, burdened banks, to smaller, independent, research-driven brokerages whose sole focus is delivering value to clients,” Slone said.
“CLSA provides a unique perspective on global equities and our aim it to position US stocks in context of global consumer and industry demand, which increasingly is being driven from Asia.”
Executive Director, Head of Equities, Calyon Securities (USA) Inc. Jay Plourde said Maris signing to the firm was a testament to the credibility of the company amongst the research and investment community.
“High calibre analysts like Maris and Mayo are attracted to the CLSA brand because we respect their judgment and provide them a platform from which to write independent, thought-provoking research. Maris fits naturally with the CLSA brand, where anti-consensus calls are the order of the day,” Plourde said.
US institutional investors have consistently voted CLSA the top research and sales brokerage for Asian equities. Through CSI, CLSA aims to become one of the top-five ranked research houses in the US.
The US research team comprises nine, US analysts based in New York and San Francisco: Michael Mayo (Banks), Rob Rutschow (Exchanges & Mid-cap banks), Chris Spahr (Asset managers), Matt Fischer (Brokers), Craig Maurer (Payment processing), Mark Urness (Energy), David Lipschitz (Metals & Mining), Srini Pajjuri (Semiconductors), Steven Fox (Technology) and Jeb Armstrong (Oil & Gas).
Maris joins CLSA’s established team of often contrarian strategists which includes global equities analyst Christopher Wood, author of the Greed&Fear newsletter; global markets analyst Russell Napier, author of Anatomy of the Bear; head of economic research Eric Fishwick; and former US diplomat and China macro-strategist, Andy Rothman.
US investors consider CLSA the top Asian brokerage for conferences and seminars. The CLSA Investor Forums are the most successful events of their kind and attract more than 5000 investors, corporations, world-leaders and industry luminaries. First held in 1994, six annual events offer a programme of unrivalled speakers who in the past have included Tony Blair, Bill Clinton, Al Gore, Alan Greenspan, Henry Kissinger, Lee Kuan Yew and Archbishop Desmond Tutu.
From 21-25 September, 2009 the flagship, 16th CLSA Investors’ Forum, will be held in Hong Kong and feature Harvard professor and author of the bestseller The Ascent of Money Niall Ferguson; The Independent Middle east correspondent Robert Fisk; academic historian and The New York Times best-selling author of The Great Influenza John Barry, and co-founder of Architecture for Humanity, Cameron Sinclair.
The third annual CLSA AsiaUSA Forum will be held in San Francisco from 1-3 March 2010.
- end -
No.1 Asian Equity Research Share (2007, 2008); No.1 Research Sales and Trading Ability (2007) - Greenwich Associates Survey for US Equity Investors in Asian Equities
No.1 Most Useful Conferences & Seminars (2006, 2007 & 2008) - Greenwich Associates Survey for US Equity Investors in Asian Equities
About David Maris
David Maris has more than 15 years experience in the specialty healthcare and healthcare investment industries. Prior to joining CSI, he was a portfolio manager for Balyasny Asset Management, a global hedge fund. Prior to which he was a leading sell-side equity research analyst with Bank of America where he managed the healthcare team. He has also previously worked for Credit Suisse First Boston, Bear Stearns and Scandinavian brokerage firm Aros Securities.
Prior to joining the sell-side in 1995, Maris was involved in the healthcare industry. He worked for pharmaceutical distributor Livingston Healthcare as well as Roberts Pharmaceutical, a leading specialty pharmaceutical company acquired by Shire Pharmaceuticals. He has an M.B.A. from Vanderbilt University and a B.A. from the University of Delaware.
About Calyon Securities (USA) Inc.
Calyon Securities (USA) Inc. offers brokerage and investment banking services. The firm provides mergers and acquisitions, valuations, debt and equity financing, leveraged and management buyouts, public offerings, privatization advice, due diligence, and transaction structuring services.
It also offers investment research, equity and debt trading, and strategic advisory services. The firm is based in New York City with additional offices in Chicago, Dallas, Houston and San Francisco. It is a subsidiary of Calyon. Calyon Securities (USA) Inc. (“CSI”) is a licensed U.S. Broker-Dealer affiliated with CLSA.
Institutional investors interested in CLSA research should contact Calyon Securities (USA) Inc. in New York on telephone: 1-212-408-5795.